154 related articles for article (PubMed ID: 25456833)
21. Structural photodynamic behavior of topotecan, a potent anticancer drug, in aqueous solutions at different pHs.
di Nunzio MR; Wang Y; Douhal A
J Phys Chem B; 2012 Jul; 116(28):8182-90. PubMed ID: 22712701
[TBL] [Abstract][Full Text] [Related]
22. Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan.
Subramanian D; Muller MT
Oncol Res; 1995; 7(9):461-9. PubMed ID: 8835290
[TBL] [Abstract][Full Text] [Related]
23. Excited state proton transfer dynamics of Topotecan inside biomimicking nanocavity.
Koninti RK; Gavvala K; Sengupta A; Hazra P
J Phys Chem B; 2015 Feb; 119(6):2363-71. PubMed ID: 25105353
[TBL] [Abstract][Full Text] [Related]
24. Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan.
Akhtar S; Beckman RA; Mould DR; Doyle E; Fields SZ; Wright J
Cancer Chemother Pharmacol; 2000; 46(3):204-10. PubMed ID: 11021737
[TBL] [Abstract][Full Text] [Related]
25. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.
Dadashzadeh S; Vali AM; Rezaie M
Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511
[TBL] [Abstract][Full Text] [Related]
26. Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis.
Bączek T; Konieczna L; Belka M; Maciejka-Kapuścińska L; Wiśniewski J; Niedźwiecki M; Balcerska A; Adamkiewicz-Drożyńska E; Wachowiak J
J Pharm Biomed Anal; 2012 Nov; 70():330-6. PubMed ID: 22658903
[TBL] [Abstract][Full Text] [Related]
27. [Studies by means of 1H NMR spectroscopy of complex formation of aromatic biologically active compounds with antibiotic topotecan].
Mosunov AA; Kostiukov VV; Evstigneev MP
Ukr Biokhim Zh (1999); 2012; 84(2):61-72. PubMed ID: 22642123
[TBL] [Abstract][Full Text] [Related]
28. Dynamic, nonsink method for the simultaneous determination of drug permeability and binding coefficients in liposomes.
Fugit KD; Anderson BD
Mol Pharm; 2014 Apr; 11(4):1314-25. PubMed ID: 24628304
[TBL] [Abstract][Full Text] [Related]
29. Repeated injections of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats.
Ma Y; Yang Q; Wang L; Zhou X; Zhao Y; Deng Y
Eur J Pharm Sci; 2012 Apr; 45(5):539-45. PubMed ID: 22155543
[TBL] [Abstract][Full Text] [Related]
30. Engineered liposomes bearing camptothecin analogue for tumour targeting:
Saraf S; Jain A; Tiwari A; Verma A; Jain SK
J Liposome Res; 2021 Dec; 31(4):326-341. PubMed ID: 32718195
[TBL] [Abstract][Full Text] [Related]
31. Interaction of clinically important human DNA topoisomerase I poison, topotecan, with double-stranded DNA.
Streltsov S; Oleinikov V; Ermishov M; Mochalov K; Sukhanova A; Nechipurenko Y; Grokhovsky S; Zhuze A; Pluot M; Nabiev I
Biopolymers; 2003; 72(6):442-54. PubMed ID: 14587067
[TBL] [Abstract][Full Text] [Related]
32. Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release.
Souza LG; Silva EJ; Martins AL; Mota MF; Braga RC; Lima EM; Valadares MC; Taveira SF; Marreto RN
Eur J Pharm Biopharm; 2011 Sep; 79(1):189-96. PubMed ID: 21352915
[TBL] [Abstract][Full Text] [Related]
33. Caffeine prevents apoptosis and cell cycle effects induced by camptothecin or topotecan in HL-60 cells.
Traganos F; Kapuscinski J; Gong J; Ardelt B; Darzynkiewicz RJ; Darzynkiewicz Z
Cancer Res; 1993 Oct; 53(19):4613-8. PubMed ID: 8402636
[TBL] [Abstract][Full Text] [Related]
34. Molecular principle of topotecan resistance by topoisomerase I mutations through molecular modeling approaches.
Pan P; Li Y; Yu H; Sun H; Hou T
J Chem Inf Model; 2013 Apr; 53(4):997-1006. PubMed ID: 23521602
[TBL] [Abstract][Full Text] [Related]
35. Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts.
Yamashita Y; Krauze MT; Kawaguchi T; Noble CO; Drummond DC; Park JW; Bankiewicz KS
Neuro Oncol; 2007 Jan; 9(1):20-8. PubMed ID: 17018695
[TBL] [Abstract][Full Text] [Related]
36. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
Rowinsky EK; Grochow LB; Sartorius SE; Bowling MK; Kaufmann SH; Peereboom D; Donehower RC
J Clin Oncol; 1996 Apr; 14(4):1224-35. PubMed ID: 8648378
[TBL] [Abstract][Full Text] [Related]
37. Assessment of ATM phosphorylation on Ser-1981 induced by DNA topoisomerase I and II inhibitors in relation to Ser-139-histone H2AX phosphorylation, cell cycle phase, and apoptosis.
Kurose A; Tanaka T; Huang X; Halicka HD; Traganos F; Dai W; Darzynkiewicz Z
Cytometry A; 2005 Nov; 68(1):1-9. PubMed ID: 16184611
[TBL] [Abstract][Full Text] [Related]
38. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH.
Gabr A; Kuin A; Aalders M; El-Gawly H; Smets LA
Cancer Res; 1997 Nov; 57(21):4811-6. PubMed ID: 9354443
[TBL] [Abstract][Full Text] [Related]
39. Optimization of vincristine-topotecan combination--paving the way for improved chemotherapy regimens by nanoliposomes.
Zucker D; Barenholz Y
J Control Release; 2010 Sep; 146(3):326-33. PubMed ID: 20685223
[TBL] [Abstract][Full Text] [Related]
40. Topotecan dynamics, tautomerism and reactivity--1H/13C NMR and ESI MS study.
Hyz K; Kawecki R; Bednarek E; Bocian W; Sitkowski J; Kozerski L
Magn Reson Chem; 2010 Aug; 48(8):575-84. PubMed ID: 20623719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
